NBTX trades 47.6% below Wall Street's consensus target of $38.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NBTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Nanobiotix S.A. (NBTX) has a Wall Street consensus price target of $38.00, based on estimates from 4 covering analysts. With the stock currently trading at $25.75, this represents a potential upside of +47.6%. The company has a market capitalization of $1.30B.
Analyst price targets range from a low of $30.00 to a high of $46.00, representing a 42% spread in expectations. The median target of $38.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NBTX trades at a trailing P/E of -45.8x. Analysts expect EPS to grow +75.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovocure Ltd | $1.7B | $14.94 | $26.00 | +74.0% | Buy | — | 15 |
 ARAYAccuray Incorporated | $33M | $0.28 | — | — | — | — | — |
 SENSSenseonics Holdings, Inc. | $413M | $9.88 | $13.75 | +39.2% | Buy | — | 17 |
 ONCOOnconetix, Inc. | $3M | $0.72 | — | — | — | — | — |
 CELCCelcuity Inc. | $3.5B | $72.10 | $159.88 | +121.7% | Buy | — | 12 |
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 CLDXCelldex Therapeutics, Inc. | $2.1B | $31.65 | $66.80 | +111.1% | Buy | — | 20 |
 NKTRNektar Therapeutics | $1.4B | $43.58 | $146.00 | +235.0% | Buy | — | 33 |
 HALOHalozyme Therapeutics, Inc. | $13.0B | $109.86 | $103.00 | -6.2% | Buy | 13.1x | 27 |
Quick answers to the most common questions about buying NBTX stock.
The consensus Wall Street price target for NBTX is $38, representing 47.6% upside from the current price of $25.75. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NBTX has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $38 implies 47.6% upside from current levels.
NBTX's current price is $25.75 with a consensus target of $38 (47.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $46 for NBTX, while the most conservative target is $30. The consensus of $38 represents the median expectation. These targets typically reflect 12-month expectations.
NBTX is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NBTX stock forecast based on 4 Wall Street analysts shows a consensus price target of $38, with estimates ranging from $30 (bear case) to $46 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NBTX, with a "Buy" consensus rating and $38 price target (47.6% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NBTX analyst price targets range from $30 to $46, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.